![Angela Mastronuzzi: We investigated whether CAR T-cells directed towards the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects](https://oncodaily.com/pub/uploads/2023/09/Angela-Mastronuzzi-photo-AIEOP-e1713045801582-1280x958.jpg)
Angela Mastronuzzi: We investigated whether CAR T-cells directed towards the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects
Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital, shared a post on LinkedIn:
” ‘GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma’ out with Clinical Cancer Research by American Association for Cancer Research.
We investigated whether chimeric antigen receptor (CAR) T-cells directed towards the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects.
Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.”
Source: Angela Mastronuzzi/LinkedIn
Angela Mastronuzzi is pediatric hematologist-oncologist and the Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy). She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies. She is the author of more than 180 scientific publications in peer-reviewed international journals.
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”